Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Research & Development (2016 - 2025)

Immucell (ICCC) has disclosed Research & Development for 16 consecutive years, with $694311.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 11.68% year-over-year to $694311.0, compared with a TTM value of $3.1 million through Sep 2025, up 0.75%, and an annual FY2024 reading of $3.9 million, down 11.29% over the prior year.
  • Research & Development was $694311.0 for Q3 2025 at Immucell, down from $831858.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.3 million in Q3 2022 and bottomed at $694311.0 in Q3 2025.
  • Average Research & Development over 5 years is $1.0 million, with a median of $1.0 million recorded in 2021.
  • The sharpest move saw Research & Development increased 21.22% in 2022, then plummeted 40.05% in 2025.
  • Year by year, Research & Development stood at $1.1 million in 2021, then dropped by 3.71% to $1.0 million in 2022, then rose by 6.58% to $1.1 million in 2023, then fell by 26.74% to $819393.0 in 2024, then decreased by 15.27% to $694311.0 in 2025.
  • Business Quant data shows Research & Development for ICCC at $694311.0 in Q3 2025, $831858.0 in Q2 2025, and $756847.0 in Q1 2025.